

**Annexure A**

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

<p>a) Name of the target entity, details in brief such as size, turnover etc.;</p>	<p>i) Name of the Target :  “Generis Farmacêutica S.A.” (Target) and its following wholly owned subsidiaries:</p> <ul style="list-style-type: none"> <li>• Mer Medicamentos, Lda.,</li> <li>• Generis Phar, Unipessoal Lda.,</li> <li>• Farma APS – Promoção de Medicamentos, Unipessoal Lda.,</li> <li>• Generis MZ, Lda.,</li> </ul> <p>hereinafter collectively referred to as “Generis”</p> <p>ii) Details of the Target:  2015 Annual Sales: € 62.7 million (Financial Year ended Dec-2015)  2016 Estimated Annual Sales: € 64.8 million</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;</p>	<p>Generis Farmacêutica S.A., is an independent company. The promoter/ promoter group/ group companies of Aurobindo Pharma Limited have no interest in the Target so the acquisition would not fall within related party transaction(s).</p>
<p>c) Industry to which the entity being acquired belongs;</p>	<p>Pharmaceuticals</p>
<p>d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</p>	<p>The acquisition establishes Aurobindo as the leading generics group in Portugal. Synergies are expected from Aurobindo’s vertical integration and pipeline breadth, improvement in Amadora plant capacity utilisation by servicing both local and European markets, and operational advantages from being the #1 generic group in Portugal</p>
<p>e) Brief details of any governmental or regulatory approvals required for the acquisition;</p>	<p>Approval from the Portuguese Competition Authority</p>
<p>f) Indicative time period for completion of the acquisition;</p>	<p>February 2017</p>
<p>g) Nature of consideration - whether cash consideration or share swap and details of the</p>	<p>Cash Consideration</p>

**AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

same	
h) Cost of acquisition or the price at which the shares are acquired;	€135 million. Aurobindo Pharma will not assume any debt as part of this transaction.
i) Percentage of shareholding / control acquired and / or number of shares acquired;	100% shareholding/ control acquired by and through Agile Pharma B.V., Netherlands, a step down wholly owned subsidiary of Aurobindo Pharma Limited, India.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Date of incorporation: 1982</p> <p>2015 Sales: € 62.7Million 2014 Sales: € 59.1Million 2013 Sales: € 58.1 Million</p> <p>Acquired entity has presence in Portugal.</p> <p>Background of business: Generis Farmacêutica S.A. is a generic pharmaceutical firm that focuses on both the retail and hospital segments apart from exports. It has a manufacturing facility in Amadora, Portugal. Generis has a wide portfolio of products with major share in the therapeutic areas of Cardiovascular, CNS, Anti-infectives, genito-urinary system medicines.</p> <p>For further details about the background of the entity and product details, refer to our press release dated 07 January 2017 attached herewith.</p>

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

## Annexure B

For immediate release

### PRESS RELEASE

7 January 2017, Hyderabad

#### Aurobindo's European Subsidiary Signs Binding Agreement to Acquire Generis Farmaceutica SA in Portugal

- "Generis" is the most sold pharmaceutical brand in Portugal, and is the #2 generic group in Portugal
- Acquisition will catapult Aurobindo Pharma Limited (APL) group to the # 1 position in the Portuguese generic pharma market
- Total consideration for the acquisition is €135mn
- Closing of the transaction is conditional on anti-trust approvals

**Hyderabad, India, January 7, 2017:** Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) today announced the signing of a binding agreement by and through its wholly owned step-down subsidiary, Agile Pharma B.V, Netherlands, to acquire Generis Farmacêutica S.A. from Magnum Capital Partners. Generis is a company engaged in the manufacture and sale of pharmaceutical products in Portugal. Closing of the transaction is conditional on obtaining necessary approvals from Portuguese authorities.

The total consideration for the acquisition is €135mn. The acquisition includes the manufacturing facility in Amadora, Portugal, which has the capacity to manufacture 1.2bn tablets/capsules/sachets annually.

This deal consolidates Aurobindo's footprint in Portugal, which currently consists of Aurovitas, Unipessoal LDA and Aurobindo Pharma (Portugal), Unipessoal Limitada. The consolidated APL group will rank #1 in the Portuguese generic pharma market, and will have the largest generic product portfolio consisting of 271 products.

Management estimates that the net sales for the acquired business will be approximately €72 million in 2017, compared to €64.8mn in 2016. Adjusted EBITDA estimate for 2016 is €12.7mn which is projected to improve to €15.8mn EBITDA in 2017.

Synergies from Aurobindo's vertical integration and pipeline breadth, improvement in Amadora plant capacity utilisation by servicing both local and European markets, and advantages from being the #1 generic group in Portugal, are expected to be €2mn in 2018, €5mn in 2019, and expected to improve further thereon.

Aurobindo has been steadily expanding its European footprint since 2006, via acquisitions across several key markets, most notably in 2014 with the acquisition of Actavis's commercial operations in seven Western European countries. The acquisition of Generis, thus, builds upon an already successful growth strategy.

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

Commenting on the transaction, Mr V. Muralidharan, SVP of European Operations for Aurobindo said: “The acquisition of Generis, by leveraging its strong portfolio and unrivalled brand recognition, will allow us to establish ourselves as the top generics player in the Portuguese market. The combined entity will benefit from a robust pipeline covering all major molecules coming off-patent in the next five years. The acquisition includes a state of the art manufacturing facility based in Portugal, which will allow us to better serve both the local Portuguese market and the broader European market, particularly with regard to small volume products and also to meet timelines for low lead time tenders. This acquisition, coupled with our past acquisition activity, underlines our commitment to focus on growth initiatives in European markets, and will be a key driver of growth for the future. Given our past experience, we expect a seamless integration of Generis with the rest of the company.”

Mr Paulo Lilaia, CEO of Generis, said: “Generis will benefit immensely from Aurobindo’s vertical integration and strong product pipeline. Our large portfolio along with our unmatched commercial presence in Portugal will allow Aurobindo to consolidate its market position in Portugal. We look forward to the opportunities this transaction will create.”

This announcement does not constitute a recommendation to shareholders or potential investors.

Campos Ferreira, Sá Carneiro & Associados, Portugal acted as the legal adviser to Aurobindo. Grant Thornton India LLP acted as the financial due diligence adviser to Aurobindo. Jefferies International Limited acted as the financial adviser to Magnum Capital Partners. Garrigues acted as the legal adviser to Magnum Capital Partners.

**About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

**For further information, please contact:**

Investor Relations  
Phone: 040-66725401 / 66725000  
Mobile: +91 98486 67906  
Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)

**Disclaimer:**

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could

**AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059  
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : [info@aurobindo.com](mailto:info@aurobindo.com)

cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

**Corp off.:** The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

**Regd. Off. :** Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)